Cancer Therapy-Induced Cardiovascular Toxicity

Guest Editors Andreas M.  Beyer, Marcelo Bonini, and Javid Moslehi, along with the editorial team of AJP-Heart and Circulatory Physiology, invite submission of original research and short reviews on the emerging area of cardio-oncology, which explores adverse cardiovascular side effects of cancer chemotherapy. 

This call for papers focuses on three major components: a) increased understanding of clinical and physiological challenges surrounding adverse cardiovascular events induced by cancer therapy that include radiation treatment as well as chemotherapy  b) improved definition of the basic mechanisms that underlie radiation/chemotherapy induced cardiovascular toxicity, and c) establishing relevant interventions to prevent or counteract the negative cardiovascular outcomes of anti-cancer therapy.

Cardio-Oncology has emerged as a new field in cardiology and medicine due to successes with cancer therapies, which have led to dramatic improvement in patient prognosis. However, these new therapies that improve cancer prognosis can also damage the cardiovascular system. Common clinical phenotypes include increased incidences of heart failure, coronary artery disease, myocarditis, pericardial disease, hypertension as well as pulmonary fibrosis, neuropathy, neurocognitive impairments, arthralgia, and immune system-related adverse events and metabolic disturbances.

With improved effectiveness of cancer treatments, the cancer-free survival rate of patients has risen. At the same time, survival due the long-term consequence on many of these therapeutic agents has declined and become of increasing clinical and scientific relevance. While most acute toxicities are adequately managed during cancer therapy and will decrease or disappear once treatment is completed, others show severe and late onset consequences that persist after completion of therapy. These persistent consequences significantly contribute to morbidity and mortality, and the underlying mechanisms are poorly understood. Novel strategies to manage and treat these adverse effects are needed to balance potential damage to the cardiovascular system of cancer patients with effective and efficient cancer treatments to fight tumor development and cancer progression.

We will consider both original research articles and review articles. For review articles only, authors should email the editorial office ( a pre-submission inquiry including a working title, author and affiliation list, abstract and brief outline of the content for approval by the editors.

All manuscripts accepted from this Call for Papers will be included in a unique online article collection to further highlight the importance of this topic. The article collection will also include specially commissioned Review articles on the topic.

All manuscripts should be submitted online at

During the online submission process, under the "Keywords & Special Sections" tab, please use the "Category" drop-down menu and select “Call for Papers Cancer Therapy-Induced Cardiovascular Toxicity."

Manuscripts will undergo normal peer review as they are received. Accepted manuscripts will be published online as they are accepted. Articles published from this Call for Papers will be highlighted with a special “Call for Papers” banner on the article PDF, as well as inclusion in the “Call for Papers: Cancer Therapy-Induced Cardiovascular Toxicity” online article collection at time of publication.

Manuscripts must be submitted by JUNE 30, 2018 to be eligible for inclusion in this Call for Papers. If you have any questions please contact Kara Hansell Keehan, Executive Editor, via email at